

BLISS GVS PHARMA LIMITED

Regd. Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.



UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2012

PART - I		STANDARD						Rs. in Lacs		PART - II		STANDARD					
Sl. No.	PARTICULARS	QUARTER ENDED			SIX MONTHS ENDED			Sl. No.	PARTICULARS	QUARTER ENDED			SIX MONTHS ENDED			YEAR END	
		30.09.2012	30.06.2012	30.03.2012	30.09.2012	30.06.2012	30.03.2012			30.09.2012	30.06.2012	30.03.2012	30.09.2012	30.06.2012	30.03.2012		
		(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)			(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)		
1	Income From Operations							1	Particulars of Shareholding								
	(a) Initial Sales (Net of Excise Duty)	12392.27	1374.16	7850.06	16666.42	13018.24	26442.51	A	Aggregated Non-promoter Shareholding								
	(b) Other Operating Income	104.24	59.86	78.88	254.00	216.00	224.93		- No. of Shares/Face Value Rs. 1/- Each	26138642	36387042	16187942	26168842	36187942	36187942		
	Total Income From Operations (Net)	10416.51	6433.82	7928.96	16920.42	13234.24	26667.44	2	Promoter and Promoter Group Shareholding								
2	Expenses								All Pledge/Encumbrance								
	(a) Consumption of Raw Materials	5157.26	2517.49	4639.01	16674.67	6813.20	14733.43		- No. of Shares/Face Value Rs. 1/- Each								
	(b) Purchase of Traded Goods	247.61	60.17	108.72	307.77	155.72	1031.29		- Percentage of Shares (%) of the total Shareholding of Promoter & Promoter Group								
	(c) Finished Pharmaceuticals Stock in Trade	292.40	209.42	161.06	22.66	17.23	51.50		- Percentage of Shares (%) of the total Shareholding of Promoter & Promoter Group								
	(d) Employee Benefit Expenses	295.06	195.62	140.55	431.88	372.45	601.15		- Percentage of Shares (%) of the total Shareholding of Promoter & Promoter Group								
	(e) Depreciation/Amortisation	110.47	105.74	143.84	217.21	226.34	394.61		- Percentage of Shares (%) of the total Shareholding of Promoter & Promoter Group								
	(f) Other Expenses	509.01	682.73	662.57	1621.60	1376.73	3193.96		- Percentage of Shares (%) of the total Shareholding of Promoter & Promoter Group								
	Total Expenses	6921.82	4264.28	6538.51	14276.20	8066.21	18913.89		Capital of the Company	64.92	64.92	64.92	64.92	64.92	64.92		
3	Profit From Operations Before Other Income & Finance Cost & Exceptional Items (1-2)	2564.69	2679.43	2390.45	5644.22	4094.03	13653.55	STATEMENT OF ASSETS AND LIABILITIES AS AT 30th SEPTEMBER, 2012. (Rs. in Lacs)									
4	Other Income	93.73	394.64	534.70	493.37	911.24	1621.06	SR. No.	PARTICULARS	STANDARD		Quarter ended 30 September 2012					
5	Profit From Ordinary Activities Before Finance Cost (1+4)	2658.42	2474.07	2925.15	6137.49	4705.27	15274.61			Sept. 12	Mar. 12						
6	Finance Cost	133.20	91.57	73.23	213.67	145.28	402.41	8	EQUITY AND LIABILITIES								
7	Profit From Ordinary Activities After Finance Cost But Before Exceptional Items (6-6)	2525.22	2382.50	2851.92	5923.82	4559.99	14872.20	1	SHAREHOLDERS' FUNDS:								
8	Exceptional Items								(a) Share Capital	1,821.47	1,821.47						
9	Profit From Ordinary Activities Before Tax (7+8)	2525.22	2382.50	2851.92	5923.82	4559.99	14872.20		(b) Reserves and Surplus	24,720.52	20,611.63						
10	Tax Expense (including Deferred Tax)	1031.72	704.01	580.59	1764.73	925.54	2168.25		Sub-total: Shareholders' funds	25,203.99	21,043.10						
11	Profit After Tax For the Period (9-10)	2423.50	1678.49	2271.33	4159.09	2634.45	12703.95	2	Share Application Reserve pending allotment								
12	Paid-Up Equity Capital	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47		Non-current liabilities								
13	Reserves Excluding Provision for Reserves (as per Balance Sheet)						20211.63		(a) Long term Borrowings	5,448.48	234.19						
14	Basic And Diluted Earnings Per Share (11-12)	2.29	1.64	2.25	4.00	2.62	5.12		(b) Deferred tax liabilities (Net)	237.76	120.17						
									(c) Other long term liabilities								
									(i) Long term provisions	51.76	51.76						
									Sub-total: Non-current liabilities	5,937.49	406.12						
									4	Current liabilities							
									(a) Short term Borrowings	2,451.93	272.18						
									(b) Trade payables	1,939.23	4,051.69						
									(c) Other current liabilities	913.19	633.20						
									(d) Short term provisions	558.61	758.26						
									Sub-total: Current liabilities	16,560.79	5,375.15						
									Total	41,620.28	27,014.17						
								9	ASSETS								
								1	Non-current assets								
									(a) Fixed Assets	4,027.02	4,055.91						
									(i) Non-current investments	2,739.58	880.71						
									(ii) Deferred tax assets								
									(iii) Long term loans and advances	8,574.27	1,683.43						
									(iv) Other non-current assets	291.50							
									Sub-total: Non-current assets	15,652.47	5,815.84						
								2	Current assets								
									(a) Current investments		31.26						
									(b) Inventories	1,821.10	1,269.09						
									(c) Trade receivables	17,035.64	12,859.02						
									(d) Short term loans and advances	5,693.68	6,790.40						
									(e) Short term loans and advances	1,130.21	872.20						
									(f) Other current assets	350.20	169.81						
									Sub-total: Current assets	25,967.81	24,135.11						
									Total	41,620.28	27,014.17						
Notes:																	
1. The company operates primarily in the Pharmaceutical Business and hence has only one reportable segment.																	
2. During the current quarter, the company has acquired 51% Stake in Citric Healthcare Africa Limited (CHCAL) a company incorporated in Kenya through its wholly owned subsidiary Bios Gas Citric Health Care Pte Ltd, Singapore for a consideration of USD 13.5 million. CHCAL through its subsidiaries is primarily engaged in health care activities.																	
3. The Statutory Auditor has certified "Unlimited Dividend" at the shareholders meeting.																	
4. The shareholders were informed by the Audit Committee & were the resolution approved by the Board at its meeting held on 11th November 2012																	
FOR BIOS GAS PHARMA LIMITED																	
654																	
S. N. KAMATH																	
MANAGING DIRECTOR																	
Place : Mumbai																	
Date : 30th November, 2012																	

Notes:

- The company operates primarily in the Pharmaceutical Business and hence has only one reportable segment.
- During the current quarter, the company has acquired SIK Sinto in Clinic Healthcare Africa Limited (SICHL) a company incorporated in Kenya through its wholly owned subsidiary Bliss GVS Clinic Health Care Pte Ltd, Singapore for a consideration of USD 13.6 million. SICHL through its subsidiaries is primarily engaged in health care activities.
- The Share Buy Back has been carried out "limited Buyback" at the above details.
- The above results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors on 10th November 2012.

FOR BLISS GVS PHARMA LIMITED
954
S. N. KAMATH
MANAGING DIRECTOR

Place: Mumbai
Date: 28th November, 2012



TOTAL INCOME UP 29.53%

PBT UP 30.01%

EPS 4.03

Head Office : Mumbai

- Tel : (022) 2200 0607 / 7318 / 6360
(022) 8631 5835 / 36
- Fax : (022) 2200 3476
- E-mail : info@bkkhareco.com
- 706 / 708, Sharda Chambers,
New Marine Lines, Mumbai 400 020

B. K. KHARE & Co.
CHARTERED ACCOUNTANTS

The Board of Directors
Bliss GVS Pharma Limited
Mumbai

Dear Sirs,

Limited Review Report

We have reviewed the accompanying statement of unaudited financial results (the Statement) of **Bliss GVS Pharma Limited** for the quarter ended 30th September 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Other Committee. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the Accounting Standards referred to in Section 211 (3C) of the Companies Act, 1956 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with stock exchanges including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B.K.Khare & Co
Chartered Accountants
Firm Registration No. 105102W

SANTOSH PARAB

Partner

M.No. 47942

Place: Mumbai

Date: 9th November 2012

Branch Office : Pune

- Tel : (020) 64019743 / 25666932 / 32926341
- E-mail : pune@bkkhareco.com
- Hotel Swaroop, 4th Floor, Lane No.10,
Prabhat Road, Erandwane, Pune - 411 004.

Branch Office : Bengaluru

- Tel : (080) 4110 5357 •
- E-mail : bkkhareb@vsnl.net •
- 101, Money Chambers, 1st Floor •
- # 6 K. H. Road, Shanthinagar, Bengaluru - 560027

BLISS GVS PHARMA LTD.

9th November 2012

To,
The Manager
National Stock Exchange
Plot no. C/1 G Block
Bandra-Kurla Complex
Bandra (E)
Mumbai: 400051

COMPANY NAME-BLISS GVS PHARMA LTD

Dear Sir,

We are enclosing the following Limited Review Report of B.K Khare & Co statutory auditor of the company, for the quarter ended 30th September, 2012

Please acknowledge and take on record the same.

Thanking you,

Yours faithfully,

For Bliss GVS Pharma Limited


Company Secretary/Authorised Signatory

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.
Tel. : (+91) (22) 42160000 / 28505387 • Fax : (+91) (22) 28563930
Email : info@blissgvs.com • Website : www.blissgvs.com

Factory : Plot No. 10 & 11, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. Palghar, Dist. Thane - 401 404.
Tel. : (+91) (2525) 252713 • Fax : (+91) (2525) 255257 • Email : factory@blissgvs.com

BLISS GVS PHARMA LTD.**BLISS
GVS**

9th November 2012

To,

The Manager
National Stock Exchange
Plot no. C/1 G Block
Bandra-Kurla Complex
Bandra (E)
Mumbai: 400051

COMPANY NAME-BLISS GVS PHARMA LTD**SUB:-Outcome of Board Meeting**

Dear Sir,

We would like to inform you that as per clause 41 of Listing Agreement the Board Meeting of the company was held on 09th November 2012 at 03: 30 p.m. at the registered office of the Company and the Board approved the following.

1. Unaudited quarterly Result for the Quarter ended 30th September 2012.

Kindly acknowledge and take on record the same.

Thanking you,

For **BLISS GVS PHARMA LTD**

Company Secretary/Authorised Signatory

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.
Tel. : (+91) (22) 42160000 / 28505387 • Fax : (+91) (22) 28563930
Email : info@blissgvs.com • Website : www.blissgvs.com

Factory : Plot No. 10 & 11, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. Palghar, Dist. Thane - 401 404.
Tel. : (+91) (2525) 252713 • Fax : (+91) (2525) 255257 • Email : factory@blissgvs.com